The Centers for Medicare and Medicaid Services (CMS) has made some minor changes to its plan to allow Medicare to negotiate some drug prices after a series of lawsuits fro
As we approach the last of our exclusive coverage of ASCO 2023, editor-in-chief Jonah Comstock speaks with Mark Reisenauer, president of US commercial at Astellas.
Legal challenges to Medicare’s price negotiation initiative introduced in the Inflation Reduction Act (IRA) continue to emerge, with pharmaceutical trade organisation PhRM
Bristol-Myers Squibb has filed a lawsuit against the US government that aims to block the drug price negotiation elements of the Inflation Reduction Act (IRA), joining fel
In a new update, the US government has more than doubled the size of the latest list of medicines subject to enforced rebates if their prices rise higher than inflation.